0001062993-21-000289.txt : 20210112 0001062993-21-000289.hdr.sgml : 20210112 20210112161049 ACCESSION NUMBER: 0001062993-21-000289 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210108 FILED AS OF DATE: 20210112 DATE AS OF CHANGE: 20210112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Petrova Penka CENTRAL INDEX KEY: 0001838044 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36596 FILM NUMBER: 21523622 MAIL ADDRESS: STREET 1: C/O TRILLIUM THERAPEUTICS INC. STREET 2: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trillium Therapeutics Inc. CENTRAL INDEX KEY: 0001616212 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 BUSINESS PHONE: (416) 595-0627 MAIL ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2021-01-08 0001616212 Trillium Therapeutics Inc. TRIL 0001838044 Petrova Penka C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 ONTARIO, CANADA 0 1 0 0 Chief Development Officer Common Shares 2021-01-08 4 M 0 2604 3.3310 A 2604 D Common Shares 2021-01-08 4 S 0 2604 15.501 D 0 D Stock Option (Right to Buy) 3.3310 2021-01-08 4 M 0 2604 0 D 2028-11-08 Common Shares 2604 57292 D This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months. /s/ James Parsons, Attorney-in-Fact 2021-01-12